NewStem

NewStem is a biotechnology R&D company. Based on its proprietary human haploid embryonic stem cell technology platform (hHESCs), NewStem has developed a diagnostic kit and created a comprehensive mutation gene library. By integrating this proprietary mutation library with the tumor genetic profile of each patient, it is expected to predict a patient’s resistance to chemotherapy before treatment begins.